TA injectable suspension (40mg/ml) (Kenalog®-40, Bridgewater, NJ) and four commercially available dissolvable sinus dressings (mAP, CMC, sPU, EH) were used in this study. Other chemicals/reagents were purchased from Fisher-Scientific (Hampton, NH).
A 6-mm sterile biopsy punch (Integra-Biosciences, Hudson, NH) was used to cut dissolvable sinus dressings to create identical volumes for this study. Dressing samples were impregnated with 50 μl of injectable suspension containing 2 mg of TA. TA-impregnated dressings were then mounted onto porous sterile cell strainers (Corning™, Kennebunk, ME) and immersed on the top of a 50 ml centrifuge tube filled with saline solution (Figure 1A ), stored in a 37 °C incubator. At 1, 2, 3, 4, 5, 7, 14, and 21 days, the saline solution underneath the filter was collected and replaced with an equal volume of saline. TA concentrations from each solution were measured using an enzyme-linked immunosorbent assay kit (Neogen, Lansing, MI) according to the manufacturer’s protocol. All samples were performed in triplicate. Statistical analysis was performed with GraphPad Prism 6.0 (La Jolla, CA). One-way ANOVA was performed with Tukey’s multiple comparison test with a significance set at p<0.05.
A 6-mm sterile biopsy punch (Integra-Biosciences, Hudson, NH) was used to cut dissolvable sinus dressings to create identical volumes for this study. Dressing samples were impregnated with 50 μl of injectable suspension containing 2 mg of TA. TA-impregnated dressings were then mounted onto porous sterile cell strainers (Corning™, Kennebunk, ME) and immersed on the top of a 50 ml centrifuge tube filled with saline solution (